BR112020018868A2 - métodos baseados em anticorpo para detectar e tratar doença de alzheimer - Google Patents
métodos baseados em anticorpo para detectar e tratar doença de alzheimer Download PDFInfo
- Publication number
- BR112020018868A2 BR112020018868A2 BR112020018868-9A BR112020018868A BR112020018868A2 BR 112020018868 A2 BR112020018868 A2 BR 112020018868A2 BR 112020018868 A BR112020018868 A BR 112020018868A BR 112020018868 A2 BR112020018868 A2 BR 112020018868A2
- Authority
- BR
- Brazil
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649208P | 2018-03-28 | 2018-03-28 | |
| US62/649,208 | 2018-03-28 | ||
| US201862664662P | 2018-04-30 | 2018-04-30 | |
| US62/664,662 | 2018-04-30 | ||
| US201862703299P | 2018-07-25 | 2018-07-25 | |
| US62/703,299 | 2018-07-25 | ||
| PCT/IB2019/000358 WO2019186276A2 (en) | 2018-03-28 | 2019-03-27 | Antibody-based methods of detecting and treating alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020018868A2 true BR112020018868A2 (pt) | 2021-01-26 |
Family
ID=66999856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020018868-9A BR112020018868A2 (pt) | 2018-03-28 | 2019-03-27 | métodos baseados em anticorpo para detectar e tratar doença de alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3774887A2 (ru) |
| JP (1) | JP2021520777A (ru) |
| KR (1) | KR20200144551A (ru) |
| CN (1) | CN112236452A (ru) |
| AU (1) | AU2019244481A1 (ru) |
| BR (1) | BR112020018868A2 (ru) |
| CA (1) | CA3095443A1 (ru) |
| IL (1) | IL277577A (ru) |
| MX (1) | MX2020009991A (ru) |
| RU (1) | RU2020135052A (ru) |
| SG (1) | SG11202008098TA (ru) |
| WO (1) | WO2019186276A2 (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201506244VA (en) | 2013-03-13 | 2015-09-29 | Prothena Biosciences Ltd | Tau immunotherapy |
| DK3452507T3 (da) | 2016-05-02 | 2022-11-14 | Prothena Biosciences Ltd | Tau-immunoterapi |
| BR112018072389A2 (pt) | 2016-05-02 | 2019-02-19 | Prothena Biosciences Limited | anticorpos que reconhecem tau |
| SG11201910066QA (en) | 2017-05-02 | 2019-11-28 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| TW202100550A (zh) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | 識別ｔａｕ之抗體 |
| CA3150156A1 (en) | 2019-09-09 | 2021-03-18 | Michal Novak | BIOMARKERS AND TREATMENTS FOR ALZHEIMER'S DISEASE AND MILD COGNITIVE DISORDER |
| EP4263599A1 (en) * | 2020-12-16 | 2023-10-25 | Voyager Therapeutics, Inc. | Tau binding compounds |
| BR112023014151A2 (pt) * | 2021-02-19 | 2023-10-10 | Eisai R&D Man Co Ltd | Anticorpo tau anti-pt217 |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN114778856B (zh) * | 2022-05-30 | 2023-03-17 | 苏州宇测生物科技有限公司 | 磷酸化tau蛋白检测试剂盒 |
| WO2024040212A2 (en) * | 2022-08-19 | 2024-02-22 | Staidson Biopharma Inc. | Antibodies specifically recognizing programmed cell death 1 ligand 1 and uses thereof |
| CN117624351B (zh) * | 2023-11-24 | 2024-07-05 | 无锡傲锐东源生物科技有限公司 | 一种抗人磷酸化tau181兔单克隆抗体及其应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
| WO1997023243A1 (en) | 1995-12-22 | 1997-07-03 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| WO1998022120A1 (en) * | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| AU2003246664B2 (en) | 2002-07-12 | 2007-06-14 | Axon Neuroscience Se | Transgenic animal expressing Alzheimer's tau protein |
| KR101111477B1 (ko) | 2002-12-03 | 2012-02-23 | 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 | 치료제와 연결된 콜레스테롤을 포함하는 접합체 |
| MXPA05006940A (es) | 2002-12-24 | 2006-02-22 | Neurochem Int Ltd | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. |
| SI1725249T1 (sl) | 2003-11-06 | 2014-04-30 | Seattle Genetics, Inc. | Spojine monometilvalina, sposobne konjugacije na ligande |
| WO2006034488A2 (en) | 2004-09-23 | 2006-03-30 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| WO2008140639A2 (en) * | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
| US8093018B2 (en) * | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
| US8613924B2 (en) * | 2009-08-06 | 2013-12-24 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
| CN109265543B (zh) | 2011-09-19 | 2022-04-26 | 阿克松神经系统科学公司 | 阿尔茨海默病中的tau蛋白介导病变的基于蛋白质的疗法和诊断 |
| SI2794654T1 (sl) * | 2011-12-20 | 2019-08-30 | Janssen Biotech, Inc. | Protitelesa proti PHF-tau njihove uporabe |
| US8853505B2 (en) * | 2012-02-27 | 2014-10-07 | Syngenta Participations Ag | Variety corn line AA2205 |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| RU2730668C2 (ru) | 2014-11-19 | 2020-08-24 | Аксон Ньюросайенс Се | Гуманизированные тау-антитела при болезни альцгеймера |
| CN107531797B (zh) * | 2016-02-05 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 凝血酶抗体、其抗原结合片段及医药用途 |
-
2019
- 2019-03-27 BR BR112020018868-9A patent/BR112020018868A2/pt unknown
- 2019-03-27 EP EP19732436.1A patent/EP3774887A2/en active Pending
- 2019-03-27 MX MX2020009991A patent/MX2020009991A/es unknown
- 2019-03-27 CA CA3095443A patent/CA3095443A1/en active Pending
- 2019-03-27 JP JP2020551506A patent/JP2021520777A/ja active Pending
- 2019-03-27 RU RU2020135052A patent/RU2020135052A/ru unknown
- 2019-03-27 KR KR1020207030584A patent/KR20200144551A/ko unknown
- 2019-03-27 CN CN201980029711.2A patent/CN112236452A/zh active Pending
- 2019-03-27 AU AU2019244481A patent/AU2019244481A1/en active Pending
- 2019-03-27 WO PCT/IB2019/000358 patent/WO2019186276A2/en unknown
- 2019-03-27 SG SG11202008098TA patent/SG11202008098TA/en unknown
-
2020
- 2020-09-24 IL IL277577A patent/IL277577A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3774887A2 (en) | 2021-02-17 |
| AU2019244481A1 (en) | 2020-10-01 |
| KR20200144551A (ko) | 2020-12-29 |
| SG11202008098TA (en) | 2020-10-29 |
| CA3095443A1 (en) | 2019-10-03 |
| WO2019186276A2 (en) | 2019-10-03 |
| JP2021520777A (ja) | 2021-08-26 |
| IL277577A (en) | 2020-11-30 |
| RU2020135052A (ru) | 2022-04-29 |
| WO2019186276A8 (en) | 2020-10-15 |
| CN112236452A (zh) | 2021-01-15 |
| MX2020009991A (es) | 2020-10-14 |
| WO2019186276A3 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020018868A2 (pt) | métodos baseados em anticorpo para detectar e tratar doença de alzheimer | |
| ES2848376T3 (es) | Anticuerpos de tau humanizados en la enfermedad de Alzheimer | |
| EP2764022B9 (en) | Phosphospecific antibodies recognising tau | |
| ES2661925T3 (es) | Anticuerpos de unión a las protofibrillas y su uso en métodos terapéuticos diagnósticos para la enfermedad de Parkinson, la demencia con cuerpos de Lewy y otras alfa-sinucleinopatías | |
| JP6124591B2 (ja) | タウオリゴマーに結合する抗体 | |
| JP6494565B2 (ja) | オリゴマー特異アミロイドベータエピトープおよび抗体 | |
| NZ738595A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| JP2019218362A (ja) | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ | |
| US20210355202A1 (en) | Antibody binding active alpha-synuclein | |
| JP6986967B2 (ja) | アルツハイマー病及び関連障害に使用するための抗体分子及びペプチド送達システム | |
| CN113651887A (zh) | 人源抗亨廷顿蛋白（htt）抗体及其用途 | |
| US20140242100A1 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
| JP2018139530A (ja) | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 | |
| WO2021205359A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| BR112020014940A2 (pt) | Adrenomedulina (adm) para diagnóstico e/ou predição de demência e ligante antiadrenomedulina para uso em terapia e prevenção de demência | |
| US20230257452A1 (en) | Anti-tau antibodies | |
| US20210139568A1 (en) | Antibody-based methods of detecting and treating alzheimer's disease | |
| US20240059766A1 (en) | Tau binding compounds | |
| JP2022502369A (ja) | α−シヌクレインの立体配座特異的エピトープ、それに対する抗体、およびそれに関連する方法 | |
| US20230365665A1 (en) | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES | |
| US20220064271A1 (en) | Methods for treating tauopathies | |
| WO2022060236A1 (en) | ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |